Logo image of ECAT

BLACKROCK ESG CAP ALL TRM TR (ECAT) Stock Price, Quote, News and Overview

NYSE:ECAT - New York Stock Exchange, Inc. - US09262F1003 - Currency: USD

16.55  -0.22 (-1.31%)

After market: 16.77 +0.22 (+1.33%)

Fundamental Rating

2

Taking everything into account, ECAT scores 2 out of 10 in our fundamental rating. ECAT was compared to 0 industry peers in the Unkown industry. ECAT may be in some trouble as it scores bad on both profitability and health. ECAT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ECAT was profitable.
ECAT had a positive operating cash flow in the past year.
ECAT Yearly Net Income VS EBIT VS OCF VS FCFECAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -500M -1B -1.5B -2B

1.2 Ratios

Industry RankSector Rank
ROA 14.91%
ROE 16.04%
ROIC 1.53%
ROA(3y)1.1%
ROA(5y)N/A
ROE(3y)0.5%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ECAT Yearly ROA, ROE, ROICECAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 10 -10

1.3 Margins

Industry RankSector Rank
OM 60.32%
PM (TTM) 497.1%
GM 62.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ECAT Yearly Profit, Operating, Gross MarginsECAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 1K 2K

More info and screens

3

2. Health

2.1 Basic Checks

ECAT has less shares outstanding than it did 1 year ago.
ECAT has a worse debt/assets ratio than last year.
ECAT Yearly Shares OutstandingECAT Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M 80M 100M
ECAT Yearly Total Debt VS Total AssetsECAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

ECAT has an Altman-Z score of 7.26. This indicates that ECAT is financially healthy and has little risk of bankruptcy at the moment.
ECAT has a debt to FCF ratio of 0.05. This is a very positive value and a sign of high solvency as it would only need 0.05 years to pay back of all of its debts.
ECAT has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Even though the debt/equity ratio score it not favorable for ECAT, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Altman-Z 7.26
ROIC/WACCN/A
WACCN/A
ECAT Yearly LT Debt VS Equity VS FCFECAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 1B -1B 2B -2B

2.3 Liquidity

ECAT has a Current Ratio of 0.10. This is a bad value and indicates that ECAT is not financially healthy enough and could expect problems in meeting its short term obligations.
ECAT has a Quick Ratio of 0.10. This is a bad value and indicates that ECAT is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
ECAT Yearly Current Assets VS Current LiabilitesECAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

ECAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 194.59%, which is quite impressive.
Looking at the last year, ECAT shows a very strong growth in Revenue. The Revenue has grown by 38.88%.
EPS 1Y (TTM)194.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%224.78%
Revenue 1Y (TTM)38.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.79%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECAT Yearly Revenue VS EstimatesECAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 10M 20M 30M 40M 50M
ECAT Yearly EPS VS EstimatesECAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 5.73, the valuation of ECAT can be described as very cheap.
The average S&P500 Price/Earnings ratio is at 29.63. ECAT is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 5.73
Fwd PE N/A
ECAT Price Earnings VS Forward Price EarningsECAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 10.18
EV/EBITDA N/A
ECAT Per share dataECAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 18.28%, ECAT is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.27, ECAT pays a better dividend.
Industry RankSector Rank
Dividend Yield 18.28%

5.2 History

ECAT has been paying a dividend for over 5 years, so it has already some track record.
ECAT has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years3
Div Non Decr Years3
ECAT Yearly Dividends per shareECAT Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

ECAT pays out 51.48% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP51.48%
EPS Next 2YN/A
EPS Next 3YN/A
ECAT Yearly Income VS Free CF VS DividendECAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 0 -500M -1B -1.5B -2B
ECAT Dividend Payout.ECAT Dividend Payout, showing the Payout Ratio.ECAT Dividend Payout.PayoutRetained Earnings

More info and screens

BLACKROCK ESG CAP ALL TRM TR

NYSE:ECAT (2/21/2025, 8:14:57 PM)

After market: 16.77 +0.22 (+1.33%)

16.55

-0.22 (-1.31%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners45.66%
Inst Owner Change-0.98%
Ins Owners0.1%
Ins Owner Change0.03%
Market Cap1.69B
Analysts0
Price TargetN/A
Short Float %0.03%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield 18.28%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP51.48%
Div Incr Years3
Div Non Decr Years3
Ex-Date02-14 2025-02-14 (0.30699)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 5.73
Fwd PE N/A
P/S 28.42
P/FCF 10.18
P/OCF 10.18
P/B 0.92
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)2.89
EY17.46%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.63
FCFY9.82%
OCF(TTM)1.63
OCFY9.82%
SpS0.58
BVpS18.05
TBVpS18.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 14.91%
ROE 16.04%
ROCE 1.94%
ROIC 1.53%
ROICexc 1.53%
ROICexgc 1.55%
OM 60.32%
PM (TTM) 497.1%
GM 62.15%
FCFM 279.14%
ROA(3y)1.1%
ROA(5y)N/A
ROE(3y)0.5%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 41133.1
Cash Conversion N/A
Profit Quality 56.15%
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 7.26
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)194.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%224.78%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)38.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y88.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.92%
OCF growth 3YN/A
OCF growth 5YN/A